207 related articles for article (PubMed ID: 14613031)
21. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion.
Hartkamp J; Troppmair J; Rapp UR
Cancer Res; 1999 May; 59(9):2195-202. PubMed ID: 10232608
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.
Dent P; Grant S
Clin Cancer Res; 2001 Apr; 7(4):775-83. PubMed ID: 11309321
[No Abstract] [Full Text] [Related]
24. MEK wars, a new front in the battle against cancer.
Duesbery NS; Webb CP; Vande Woude GF
Nat Med; 1999 Jul; 5(7):736-7. PubMed ID: 10395314
[No Abstract] [Full Text] [Related]
25. Activation of the extracellular signal-regulated kinase pathway is differentially required for TCR-stimulated production of six cytokines in primary T lymphocytes.
Egerton M; Fitzpatrick DR; Kelso A
Int Immunol; 1998 Feb; 10(2):223-9. PubMed ID: 9533450
[TBL] [Abstract][Full Text] [Related]
26. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
Chilamakuri R; Agarwal S
Curr Oncol; 2022 Sep; 29(9):6508-6522. PubMed ID: 36135081
[TBL] [Abstract][Full Text] [Related]
27. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T
Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
[TBL] [Abstract][Full Text] [Related]
28. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.
Squires MS; Nixon PM; Cook SJ
Biochem J; 2002 Sep; 366(Pt 2):673-80. PubMed ID: 12069688
[TBL] [Abstract][Full Text] [Related]
29. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway.
Mody N; Leitch J; Armstrong C; Dixon J; Cohen P
FEBS Lett; 2001 Jul; 502(1-2):21-4. PubMed ID: 11478941
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
31. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
32. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
34. MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.
Xiao L; Pimental DR; Amin JK; Singh K; Sawyer DB; Colucci WS
J Mol Cell Cardiol; 2001 Apr; 33(4):779-87. PubMed ID: 11273730
[TBL] [Abstract][Full Text] [Related]
35. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
[TBL] [Abstract][Full Text] [Related]
36. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy.
Choukroun G; Hajjar R; Kyriakis JM; Bonventre JV; Rosenzweig A; Force T
J Clin Invest; 1998 Oct; 102(7):1311-20. PubMed ID: 9769323
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells.
Stadheim TA; Xiao H; Eastman A
Cancer Res; 2001 Feb; 61(4):1533-40. PubMed ID: 11245462
[TBL] [Abstract][Full Text] [Related]
38. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells.
Watters JJ; Chun TY; Kim YN; Bertics PJ; Gorski J
Mol Endocrinol; 2000 Nov; 14(11):1872-81. PubMed ID: 11075818
[TBL] [Abstract][Full Text] [Related]
39. Insulin activates p38 mitogen-activated protein (MAP) kinase via a MAP kinase kinase (MKK) 3/MKK 6 pathway in vascular smooth muscle cells.
Igarashi M; Yamaguchi H; Hirata A; Daimon M; Tominaga M; Kato T
Eur J Clin Invest; 2000 Aug; 30(8):668-77. PubMed ID: 10964158
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Lorusso PM; Adjei AA; Varterasian M; Gadgeel S; Reid J; Mitchell DY; Hanson L; DeLuca P; Bruzek L; Piens J; Asbury P; Van Becelaere K; Herrera R; Sebolt-Leopold J; Meyer MB
J Clin Oncol; 2005 Aug; 23(23):5281-93. PubMed ID: 16009947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
